FDA staff cite concerns over Amgen's cancer vaccine data

April 27 (Reuters) - The U.S. Food and Drug Administration should not consider an accelerated review for drugmaker Amgen Inc's marketing application for its skin cancer vaccine, FDA staff reviewers concluded in documents released on Monday.